Aller au contenu principal
Accès ouvert déclaré 2025 article

Differential platelet protein release profiles in community-acquired pneumonia and COVID-19

2Citations signalées — pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Introduction Platelets play a crucial role, amongst others, in the host response to infection through the release of proinflammatory and procoagulant proteins. Pneumonia represents a major disease burden, which has further increased since the onset of the coronavirus disease 2019 (COVID-19) pandemic. We aimed to determine platelets’ protein release profiles in hospitalised patients with non-COVID community-acquired pneumonia (CAP) or COVID-19. Methods Platelets from patients with CAP or COVID-19 and from control subjects were incubated with platelet receptor agonists stimulating either glycoprotein (GP)VI or protease-activated receptor 1 (PAR1), or medium (spontaneous release); nine platelet products were measured in supernatants. Platelet activation was also assessed by measuring P-selectin and active GPIIbIIIa surface expression by flow cytometry. Results We enrolled 32 patients with CAP, 104 patients with COVID-19 and 47 control subjects. Platelets from CAP patients spontaneously released less chemokines as compared to controls, which sharply contrasted with the platelets’ release profile in COVID-19, which was characterised by enhanced release of chemokines, plasminogen activator inhibitor 1 (PAI-1) and CD40 ligand relative to both controls and CAP patients. These differences were partially maintained uponex vivostimulation of GPVI or PAR1. Enhanced GPVI-induced platelet release of P-selectin, CD40 ligand, PAI-1 and CCL5 was associated with an increased risk for the need of (non)invasive ventilation and/or mortality in COVID-19 patients. Platelet expression of P-selectin and GPIIbIIIa did not differ between groups. Conclusion Platelet release profiles differ strongly between CAP and COVID-19 patients, wherein platelets from COVID-19 patients released more bioactive products, linking with an adverse clinical outcome.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Differential platelet protein release profiles in community-acquired pneumonia and COVID-19
Date Crossref
27/02/2025
Éditeur
European Respiratory Society (ERS)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

COVID-19 Clinical Research StudiesPlatelet Disorders and TreatmentsAntiplatelet Therapy and Cardiovascular Diseases

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.